Home Infusion Therapy Market: Impacts of Regulatory Changes and Policies

 The global home infusion therapy market was valued at USD 38.66 billion in 2024 and is projected to grow to USD 61.72 billion by 2030, reflecting a compound annual growth rate (CAGR) of 8.2% from 2025 to 2030. Home infusion therapy entails the delivery of treatments, medications, or fluids directly into a patient’s bloodstream via intravenous (IV) infusion, typically within the comfort and convenience of their own home.

 

Several key factors are driving this market's growth, such as the increasing geriatric population with reduced mobility, a rising preference for home care, and rapid technological advancements. Infusion therapy, which includes essential components like IV therapy and IV hydration therapy, is vital for treating conditions such as immune deficiencies, cancer, and congestive heart failure, where oral medications are ineffective. The steadily increasing demand for these therapies is largely due to the necessity for long-term treatment among patients, positioning home infusion therapy as a notably cost-effective alternative to traditional hospital care. By providing IV therapy and hydration services, it enhances patient access to effective and personalized medical solutions from home.

 

A significant factor promoting the adoption of home infusion therapy within global healthcare systems is its cost-effectiveness. Administering IV treatments outside hospital settings drastically reduces expenses linked to inpatient care, such as hospital admissions, re-admissions, and longer stays. This model not only lowers direct treatment costs but also minimizes ancillary expenses, including facility overhead and staffing. Home infusion therapy offers considerable savings compared to conventional inpatient care, making it an appealing option for both patients and healthcare payers. For example, according to the National Home Infusion Association (NHIA), the cost of home infusion therapy ranges from USD 122 to USD 225 per day, whereas inpatient care can vary from USD 586 to USD 798 per day, depending on the type of therapy administered.

 

Key Market Trends & Insights

• North America held the largest market share at 56.6% in 2024, driven by increased R&D and the adoption of new technologies in infusion pumps. The growing need for long-term therapy for patients with specific conditions fuels the regional market.
• The U.S. home infusion therapy market is expected to expand during the forecast period, mainly due to the rise in chronic diseases and the cost-effectiveness of home-based care. Medicare supports home infusion services such as nursing visits, caregiver training, and patient monitoring for certain intravenous or subcutaneous drugs administered at home.
• By type, the services segment dominated the home infusion therapy market, accounting for 72.4% of global revenue in 2024. This dominance is primarily due to the heightened demand for clinical interventions, including anti-infective therapy, parenteral nutrition, chemotherapy, hydration therapy, and pain management within home settings.
• In terms of application, anti-infectives led the market with the highest revenue share in 2024, attributed to the notable number of procedures related to the administration of antifungal and antibiotic medications. This approach also helps minimize patient exposure to other hospital-acquired infections (HAIs).

 

Order a free sample PDF of the Home Infusion Therapy Market Intelligence Study, published by Grand View Research.

 

Market Size & Forecast

• 2024 Market Size: USD 38.66 Billion
• 2030 Projected Market Size: USD 61.72 Billion
• CAGR (2025-2030): 8.2%
• North America: Largest market in 2024

 

Key Companies & Market Share Insights

Prominent companies in the home infusion therapy market include Option Care Health, Inc., Baxter, and Fresenius Kabi AG.

• Baxter is a global healthcare company with a diverse range of medical products, therapies, and technologies, evolving into a leading industry player since its inception in the 1930s. The company focuses on innovative solutions for critical medical needs, including renal care, medication delivery, and various therapeutic areas.
• Becton, Dickinson, and Company (BD) is a global medical technology firm specializing in medical devices, laboratory equipment, and diagnostic products that enhance the diagnosis and treatment of various conditions. Committed to healthcare improvement, BD provides solutions in medication management, infection prevention, diagnostics, and biosciences.

 

Key Players

• Baxter
• B. Braun SE
• BD
• Fresenius Kabi AG
• ICU Medical, Inc.
• Terumo Corporation
• JMS Co. Ltd.
• Option Care Health, Inc.
• CareCentrix, Inc.
• Coram LLC.
• PharMerica Corporation
• Moog Inc.
• Amedisys, Inc.

 

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

 

Conclusion

The home infusion therapy market is poised for significant growth due to demographic shifts, technological advancements, and economic benefits associated with home-based care. With increasing demand for long-term treatments, the sector offers a compelling alternative to traditional inpatient therapies, promising both accessibility and affordability for patients globally.